337 related articles for article (PubMed ID: 15082596)
21. Non-alcoholic fatty liver disease - histological scoring systems: a large cohort single-center, evaluation study.
Rastogi A; Shasthry SM; Agarwal A; Bihari C; Jain P; Jindal A; Sarin S
APMIS; 2017 Nov; 125(11):962-973. PubMed ID: 29076589
[TBL] [Abstract][Full Text] [Related]
22. Predictors of steatohepatitis and advanced fibrosis in non-alcoholic fatty liver disease.
Pagadala M; Zein CO; McCullough AJ
Clin Liver Dis; 2009 Nov; 13(4):591-606. PubMed ID: 19818307
[TBL] [Abstract][Full Text] [Related]
23. Validation of liver fibrosis biomarker (FibroTest) for assessing liver fibrosis progression: proof of concept and first application in a large population.
Poynard T; Munteanu M; Deckmyn O; Ngo Y; Drane F; Castille JM; Housset C; Ratziu V; Imbert-Bismut F
J Hepatol; 2012 Sep; 57(3):541-8. PubMed ID: 22612998
[TBL] [Abstract][Full Text] [Related]
24. Long-term survival and cause-specific mortality in patients with cirrhosis of the liver: a nationwide cohort study in Denmark.
Sørensen HT; Thulstrup AM; Mellemkjar L; Jepsen P; Christensen E; Olsen JH; Vilstrup H
J Clin Epidemiol; 2003 Jan; 56(1):88-93. PubMed ID: 12589875
[TBL] [Abstract][Full Text] [Related]
25. The natural history of non-alcoholic fatty liver disease.
Caldwell S; Argo C
Dig Dis; 2010; 28(1):162-8. PubMed ID: 20460906
[TBL] [Abstract][Full Text] [Related]
26. Incidence and risk factors for non-alcoholic steatohepatitis: prospective study of 5408 women enrolled in Italian tamoxifen chemoprevention trial.
Bruno S; Maisonneuve P; Castellana P; Rotmensz N; Rossi S; Maggioni M; Persico M; Colombo A; Monasterolo F; Casadei-Giunchi D; Desiderio F; Stroffolini T; Sacchini V; Decensi A; Veronesi U
BMJ; 2005 Apr; 330(7497):932. PubMed ID: 15746106
[TBL] [Abstract][Full Text] [Related]
27. Mild drinking habit is a risk factor for hepatocarcinogenesis in non-alcoholic fatty liver disease with advanced fibrosis.
Kimura T; Tanaka N; Fujimori N; Sugiura A; Yamazaki T; Joshita S; Komatsu M; Umemura T; Matsumoto A; Tanaka E
World J Gastroenterol; 2018 Apr; 24(13):1440-1450. PubMed ID: 29632425
[TBL] [Abstract][Full Text] [Related]
28. Role of liver biopsy and serum markers of liver fibrosis in non-alcoholic fatty liver disease.
Adams LA; Angulo P
Clin Liver Dis; 2007 Feb; 11(1):25-35, viii. PubMed ID: 17544970
[TBL] [Abstract][Full Text] [Related]
29. Risk of cancer in patients hospitalized with fatty liver: a Danish cohort study.
Sørensen HT; Mellemkjaer L; Jepsen P; Thulstrup AM; Baron J; Olsen JH; Vilstrup H
J Clin Gastroenterol; 2003 Apr; 36(4):356-9. PubMed ID: 12642745
[TBL] [Abstract][Full Text] [Related]
30. Fibrosis stage but not NASH predicts mortality and time to development of severe liver disease in biopsy-proven NAFLD.
Hagström H; Nasr P; Ekstedt M; Hammar U; Stål P; Hultcrantz R; Kechagias S
J Hepatol; 2017 Dec; 67(6):1265-1273. PubMed ID: 28803953
[TBL] [Abstract][Full Text] [Related]
31. The role of liver biopsy in the diagnosis and prognosis of patients with acute deterioration of alcoholic cirrhosis.
Mookerjee RP; Lackner C; Stauber R; Stadlbauer V; Deheragoda M; Aigelsreiter A; Jalan R
J Hepatol; 2011 Nov; 55(5):1103-11. PubMed ID: 21376092
[TBL] [Abstract][Full Text] [Related]
32. Functional impairment in alcoholic liver disease and non-alcoholic fatty liver disease is significant and persists over 3 years of follow-up.
Elliott C; Frith J; Day CP; Jones DE; Newton JL
Dig Dis Sci; 2013 Aug; 58(8):2383-91. PubMed ID: 23609794
[TBL] [Abstract][Full Text] [Related]
33. Characteristics and diagnosis of NAFLD/NASH.
Hashimoto E; Taniai M; Tokushige K
J Gastroenterol Hepatol; 2013 Dec; 28 Suppl 4():64-70. PubMed ID: 24251707
[TBL] [Abstract][Full Text] [Related]
34. Long-term prognosis of patients with alcoholic liver cirrhosis: a 15-year follow-up study of 100 Norwegian patients admitted to one unit.
Bell H; Jahnsen J; Kittang E; Raknerud N; Sandvik L
Scand J Gastroenterol; 2004 Sep; 39(9):858-63. PubMed ID: 15513384
[TBL] [Abstract][Full Text] [Related]
35. Alcoholic liver disease presents at advanced stage and progresses faster compared to non-alcoholic fatty liver diseas.
Shoreibah M; Raff E; Bloomer J; Kakati D; Rasheed K; Kuo YF; Singal AK
Ann Hepatol; 2016; 15(2):183-9. PubMed ID: 26845595
[TBL] [Abstract][Full Text] [Related]
36. [Non-alcoholic fatty liver disease and cardiovascular risk].
Abel T; Fehér J
Orv Hetil; 2008 Jul; 149(28):1299-305. PubMed ID: 18617457
[TBL] [Abstract][Full Text] [Related]
37. Transient elastography as a screening tool for liver fibrosis and cirrhosis in a community-based population aged over 45 years.
Roulot D; Costes JL; Buyck JF; Warzocha U; Gambier N; Czernichow S; Le Clesiau H; Beaugrand M
Gut; 2011 Jul; 60(7):977-84. PubMed ID: 21068129
[TBL] [Abstract][Full Text] [Related]
38. Could post-liver transplantation course be helpful for the diagnosis of so called cryptogenic cirrhosis?
Duclos-Vallée JC; Yilmaz F; Johanet C; Roque-Afonso AM; Gigou M; Trichet C; Féray C; Ballot E; Dussaix E; Castaing D; Bismuth H; Samuel D; Guettier C
Clin Transplant; 2005 Oct; 19(5):591-9. PubMed ID: 16146549
[TBL] [Abstract][Full Text] [Related]
39. [Predictors of liver fibrosis in patients with non-alcoholic fatty liver disease. The role of metabolic syndrome, insulin-resistance and inflammation].
Andreozzi P; Viscogliosi G; Colella F; Subic M; Cipriani E; Marigliano B; Verrusio W; Servello A; Ettorre E; Marigliano V
Recenti Prog Med; 2012 Dec; 103(12):570-4. PubMed ID: 23258240
[TBL] [Abstract][Full Text] [Related]
40. Increased prevalence of chronic kidney disease in patients with Type 1 diabetes and non-alcoholic fatty liver.
Targher G; Pichiri I; Zoppini G; Trombetta M; Bonora E
Diabet Med; 2012 Feb; 29(2):220-6. PubMed ID: 21883436
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
